GSM is the clinical term for the vaginal, vulvar, and urinary symptoms caused by estrogen decline during and after menopause. It includes vaginal dryness, painful sex, burning, irritation, urinary urgency, and recurrent UTIs. The term replaced “vaginal atrophy” in 2014 because the older name was incomplete and implied irreversible damage. GSM is estimated to affect 40–60% of postmenopausal women, is chronic and progressive without treatment, and unlike hot flashes, does not improve on its own. Effective treatments exist — from vaginal moisturizers to low-dose vaginal estrogen — but most women are never offered them because the conversation never happens.
If you have been dealing with vaginal dryness that won’t resolve, sex that has gone from uncomfortable to painful, a sudden increase in UTIs, or a persistent burning and irritation that no one can explain — you are likely experiencing a medical condition with a clinical name, a well-understood cause, and a range of effective treatments.
The condition is called Genitourinary Syndrome of Menopause, or GSM. And the reason you probably haven’t heard of it isn’t that it’s rare. It’s because the medical system has been remarkably slow at talking to women about what happens to their vaginal and urinary health after estrogen declines.
This article is the conversation your doctor’s appointment didn’t have time for. I’m going to explain what GSM is, what causes it, why it behaves the way it does, and what the evidence says about treating it — including a significant regulatory change in November 2025 that may alter the options available to you.
GSM: The Name and Why It Matters
Until 2014, what we now call GSM was referred to as “vaginal atrophy” or “atrophic vaginitis.” Those names had two problems. First, they focused entirely on the vagina, ignoring the fact that the same estrogen-driven tissue changes also affect the vulva, the urethra, and the bladder. Second, the word “atrophy” implied deterioration that couldn’t be reversed — which is inaccurate, because the tissue changes of GSM respond to treatment.
In 2014, The Menopause Society (then NAMS) and the International Society for the Study of Women’s Sexual Health jointly adopted the term Genitourinary Syndrome of Menopause (Portman & Gass, Menopause, 2014). GSM describes the full spectrum: genital symptoms (dryness, burning, irritation), sexual symptoms (pain with intercourse, decreased arousal, reduced lubrication), and urinary symptoms (urgency, frequency, recurrent infections). One condition. One cause. Multiple systems affected.
Knowing the name matters for a practical reason: when you walk into your doctor’s office and say “I think I have GSM,” you are speaking in their clinical language. You are naming a recognized condition with established guidelines. That changes the conversation from vague complaint to specific diagnosis.
What Causes GSM
GSM is caused by estrogen decline. That sentence is simple, but its consequences are not.
Estrogen does far more than regulate your menstrual cycle. It maintains the structural integrity of tissues throughout the genitourinary tract. When estrogen levels drop — gradually through perimenopause, then more sharply at menopause — the effects cascade across the vagina, vulva, urethra, and bladder.
What Estrogen Loss Does to Your Tissue
The vaginal walls are lined with multiple layers of cells that depend on estrogen to maintain their thickness, moisture, and resilience. When estrogen declines, those cell layers thin. Collagen is lost. Blood flow to the vaginal walls decreases. Natural lubrication drops. The vaginal pH shifts from its healthy acidic range (around 3.5–4.5) to a more alkaline state, which disrupts the protective microbiome — the Lactobacillus bacteria that keep the environment healthy — and makes the tissue more vulnerable to irritation and infection.
The vulvar tissue also thins and loses fullness. The clitoris and labia may become less sensitive. The urethral lining, which shares the same embryological origin as vaginal tissue and is equally estrogen-dependent, becomes more fragile — which is why urinary urgency, frequency, and recurrent UTIs are part of the same syndrome, not separate problems.
Recent research also highlights the role of declining androgens — testosterone and its precursor DHEA — in GSM. The vagina contains androgen receptors, and when both estrogen and androgen levels drop, the tissue changes are compounded (Simon et al., Sexual Medicine Reviews, 2026).
Why This Is Different from Hot Flashes
This is the distinction most women never hear, and it changes everything about how you approach treatment.
Hot flashes are driven by the vasomotor system’s adjustment to changing estrogen levels. For many women, hot flashes peak and then gradually diminish over several years as the body recalibrates. They are uncomfortable, sometimes severely disruptive, but they tend to have a natural endpoint.
GSM is the opposite. It is progressive. Without treatment, the tissue changes continue. Vaginal walls become thinner. Lubrication decreases further. The urinary symptoms compound. There is no natural recalibration. The estrogen those tissues need is not coming back, and the damage accumulates over time. The 2025 AUA/SUFU/AUGS guideline explicitly states that long-term treatment and follow-up may be required to manage GSM.
Hot flashes often improve on their own. GSM does not. That distinction is the reason early treatment matters.
The Full Symptom Picture
GSM is not one symptom. It is a syndrome — a collection of related changes that present differently in different women. Some experience primarily vaginal symptoms. Some experience primarily urinary symptoms. Most experience a combination that shifts over time.
| Category | Symptoms |
|---|---|
| Vaginal | Dryness, burning, irritation, discharge changes, narrowing of the vaginal canal |
| Vulvar | Itching, thinning of the labia, loss of vulvar fullness, discomfort with clothing or sitting |
| Sexual | Pain during intercourse (dyspareunia), decreased arousal and lubrication, reduced orgasm intensity, bleeding after sex |
| Urinary | Urgency, increased frequency, recurrent UTIs, burning with urination, stress incontinence |
One of the most under-recognized connections is between GSM and recurrent UTIs. Many postmenopausal women are prescribed repeated rounds of antibiotics for UTIs without anyone investigating the underlying cause. The pH and microbiome changes that GSM creates in the vaginal and urethral tissue make these women significantly more susceptible to infection — and treating the GSM, rather than just the individual UTI, is the more effective long-term approach.
How GSM Is Diagnosed
Here is something that may reassure you: GSM does not require a blood test or a hormone panel. The 2025 AUA/SUFU/AUGS guideline is clear on this — diagnosis is based on your reported symptoms and, when appropriate, a physical examination. Clinicians are specifically advised not to rely on hormone levels for diagnosis or management decisions.
If you are in perimenopause or postmenopause and you are experiencing the symptoms described above — dryness, burning, pain with sex, urinary urgency, recurrent UTIs — the diagnosis is GSM until proven otherwise. Physical signs like vaginal tissue thinning, reduced vaginal folds, or changes in pH may support the diagnosis, but they are not required for it.
This matters because many women are told their labs are “normal” and sent home without treatment. GSM is a clinical diagnosis based on symptoms and exam, not on a lab value. If you are experiencing these symptoms, a normal hormone panel does not mean GSM isn’t present.
What Works: The Treatment Landscape
Effective treatment options exist across a spectrum from over-the-counter to prescription. The right approach depends on symptom severity, your medical history, and what you’re comfortable with. I’m going to outline what the evidence supports — and a major recent change in how the safety of one key option is understood.
First Line: Moisturizers and Lubricants
For mild GSM, over-the-counter vaginal moisturizers and lubricants are the recommended starting point. These are two different products with different purposes. Lubricants reduce friction during sexual activity. Moisturizers are used regularly — typically two to three times per week — to restore and maintain vaginal tissue hydration independent of sex.
If you are only using a lubricant during sex and wondering why the dryness and discomfort persist between encounters, this is why. Consistent moisturizer use addresses the tissue itself, not just the friction.
The specific products, how they compare, and which evidence supports each are covered in detail in our dedicated comparison articles linked below. This article focuses on understanding the condition itself.
Gold Standard: Low-Dose Vaginal Estrogen
This is the most effective treatment for moderate to severe GSM. Vaginal estrogen is applied directly to the vaginal tissue — as a cream, tablet, ring, or suppository — and works locally to rebuild tissue thickness, restore elasticity, improve lubrication, normalize pH, and reduce urinary symptoms including recurrent UTIs.
Vaginal estrogen is not the same as systemic hormone therapy. It acts locally, with minimal absorption into the bloodstream. This is an important distinction because the safety concerns that dominated the conversation about hormone therapy for two decades were based on systemic oral estrogen in older women — a very different therapy than low-dose vaginal application.
In November 2025, the FDA removed the boxed warning from low-dose vaginal estrogen products. This was a significant regulatory change. The original warning, applied broadly in 2003, was based on Women’s Health Initiative data that studied oral conjugated estrogens in women with an average age of 63. The FDA, The Menopause Society, the AUA, and ACOG all determined that the warning was outdated and did not accurately reflect the safety of local vaginal formulations. Experts agree that vaginal estrogen does not increase the risks of heart disease, stroke, or breast cancer.
The 2025 AUA/SUFU/AUGS guideline issues a strong recommendation that clinicians should offer local low-dose vaginal estrogen to patients with GSM.
Note for breast cancer survivors: The safety of vaginal estrogen in women with a history of estrogen-receptor-positive breast cancer is an evolving area of research. Recent evidence is increasingly reassuring, but this decision should be made with your oncology team, not independently. Non-hormonal options remain fully available and effective for women in this situation.
Other Prescription Options
Vaginal DHEA (prasterone): An intravaginal insert of dehydroepiandrosterone, which is converted locally into both estrogens and androgens. FDA-approved for moderate to severe GSM-related painful sex. Offers an alternative mechanism for women who want a different approach from direct estrogen.
Ospemifene: An oral selective estrogen receptor modulator (SERM) that acts on vaginal tissue without being an estrogen. FDA-approved for moderate to severe dyspareunia due to GSM. Taken as a daily pill. May be appropriate for women who prefer a non-vaginal delivery route.
Pelvic Floor Physical Therapy
GSM and pelvic floor dysfunction frequently coexist. The tissue changes of GSM can trigger or worsen pelvic floor tightening (hypertonus), which adds a muscular layer of pain on top of the tissue-level dryness and fragility. The 2025 AUA guideline specifically recommends that clinicians may refer GSM patients with pelvic floor dysfunction to a physical therapist specializing in pelvic health.
If vaginal estrogen or moisturizers address the tissue but sex remains painful, pelvic floor involvement is likely and should be evaluated.
What to Say to Your Doctor
If you suspect you have GSM, the most effective thing you can do is name it. Here is a sentence you can take to your next appointment:
“I’m experiencing vaginal dryness, pain with sex, and urinary urgency. I believe this may be Genitourinary Syndrome of Menopause. I’d like to discuss treatment options, including vaginal estrogen.”
That framing does three things. It names specific symptoms. It uses the clinical term, which signals that you have done your research. And it opens the door to a treatment conversation rather than waiting for your provider to bring it up — which, statistically, they are unlikely to do.
If your provider is unfamiliar with GSM or dismisses your symptoms as normal aging, a menopause-certified specialist can be found through The Menopause Society’s provider directory. You deserve a clinician who takes this seriously.
The Bottom Line
GSM is a recognized medical condition with a specific cause, a predictable course, and effective treatments. It is not a cosmetic concern. It is not a normal part of aging that you should accept. It is not something that will resolve with patience.
It is a progressive, estrogen-driven change to the tissues of your vagina, vulva, and urinary tract — and the earlier you address it, the more responsive the tissue is to treatment. That is the clinical reality, and it is the reason I wrote this article: because the women who find it at 2am while searching “why does it burn when I pee after menopause” deserve an answer that names the condition, explains the biology, and tells them exactly what to do next.
You have the name now. Use it.